中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2015年
3期
189-193
,共5页
胰腺癌%microRNA%诊断%预后
胰腺癌%microRNA%診斷%預後
이선암%microRNA%진단%예후
Pancreatic cancer%MicroRNA%Diagnosis%Prognosis
目的 研究血清miR-155对胰腺癌诊断和预后评估的价值.方法 前瞻性募集了2009年1月至2013年8月到合肥市第一人民医院就诊的首诊胰腺癌患者110例,慢性胰腺癌患者70例,健康个体58例,采用实时PCR检测了其血清miR-155丰度.采用受试者工作特征曲线分析miR-155对胰腺癌的诊断价值,并分析miR-155与患者TNM分期、CA19-9的关系.以Kaplan-Meier法和Cox风险比例模型评价miR-155对胰腺癌的预后评估价值.结果 胰腺癌患者血清miR-155水平较慢性胰腺炎患者和健康个体明显增高(均P ＜0.05).miR-155诊断胰腺癌的曲线下面积为0.82(95％CI:0.75 ～0.88),联合miR-155和CA19-9诊断胰腺癌的曲线下面积为0.88(95％ CI:0.82～0.93).miR-155随着胰腺癌TNM分期的递进而逐渐增高(P＜0.05),且与CA19-9呈正相关(R2=0.22,P＜0.05).miR-155≥1.46 ACT与胰腺癌病死率独立相关,其风险比为2.88(95％ CI:1.26～6.58).结论 血清miR-155是对胰腺癌诊断和预后评估有价值的标志物.
目的 研究血清miR-155對胰腺癌診斷和預後評估的價值.方法 前瞻性募集瞭2009年1月至2013年8月到閤肥市第一人民醫院就診的首診胰腺癌患者110例,慢性胰腺癌患者70例,健康箇體58例,採用實時PCR檢測瞭其血清miR-155豐度.採用受試者工作特徵麯線分析miR-155對胰腺癌的診斷價值,併分析miR-155與患者TNM分期、CA19-9的關繫.以Kaplan-Meier法和Cox風險比例模型評價miR-155對胰腺癌的預後評估價值.結果 胰腺癌患者血清miR-155水平較慢性胰腺炎患者和健康箇體明顯增高(均P ＜0.05).miR-155診斷胰腺癌的麯線下麵積為0.82(95％CI:0.75 ～0.88),聯閤miR-155和CA19-9診斷胰腺癌的麯線下麵積為0.88(95％ CI:0.82～0.93).miR-155隨著胰腺癌TNM分期的遞進而逐漸增高(P＜0.05),且與CA19-9呈正相關(R2=0.22,P＜0.05).miR-155≥1.46 ACT與胰腺癌病死率獨立相關,其風險比為2.88(95％ CI:1.26～6.58).結論 血清miR-155是對胰腺癌診斷和預後評估有價值的標誌物.
목적 연구혈청miR-155대이선암진단화예후평고적개치.방법 전첨성모집료2009년1월지2013년8월도합비시제일인민의원취진적수진이선암환자110례,만성이선암환자70례,건강개체58례,채용실시PCR검측료기혈청miR-155봉도.채용수시자공작특정곡선분석miR-155대이선암적진단개치,병분석miR-155여환자TNM분기、CA19-9적관계.이Kaplan-Meier법화Cox풍험비례모형평개miR-155대이선암적예후평고개치.결과 이선암환자혈청miR-155수평교만성이선염환자화건강개체명현증고(균P ＜0.05).miR-155진단이선암적곡선하면적위0.82(95％CI:0.75 ～0.88),연합miR-155화CA19-9진단이선암적곡선하면적위0.88(95％ CI:0.82～0.93).miR-155수착이선암TNM분기적체진이축점증고(P＜0.05),차여CA19-9정정상관(R2=0.22,P＜0.05).miR-155≥1.46 ACT여이선암병사솔독립상관,기풍험비위2.88(95％ CI:1.26～6.58).결론 혈청miR-155시대이선암진단화예후평고유개치적표지물.
Objective To investigate the diagnostic and prognostic value of serum miR-155 for pancreatic cancer.Methods A total of 110 pancreatic cancer patients,70 chronic pancreatitis and 58 healthy individuals who admitted to the First People's Hospital of Hefei between January 2009 and August 2013 were prospectively enrolled.Their serum miR-155 levels were detected by real-time PCR.The receiver operating characteristic curve was employed to estimate the diagnostic accuracy of miR-155 for pancreatic cancer.Correlations between miR-155,carbohydrate antigen 19-9 (CA 19-9) and TNM stages were analyzed.The Kap1an-Meier approach and the Cox model were used to assess the prognostic value of miR-155 for pancreatic cancer.Results Pancreatic cancer patients had significantly higher serum miR-155 when compared either with chronic pancreatitis patients or healthy individuals (P ＜ 0.05 for both).The areas under the receiver operating characteristic curve were 0.82 (95％ CI:0.75 ～ 0.88) for miR-155,and 0.88 (95％ CI:0.82 ～0.93) for miR-155 combined with CA19-9.MiR-155 increased as the TNM stages advanced,and it was positively correlated with CA 19-9 (R2 =0.22,P ＜ 0.05).MiR-155 ≥ 1.46 △CT was independently associated with pancreatic cancer mortality,with a hazard ration of 2.88 (95％ CI:1.26 ～ 6.58).Conclusion Serum miR-155 is a useful biomarker for diagnosis and prognosis of pancreatic cancer.
